news
Pembrolizumab plus chemo improves endometrial cancer survival
An interim analysis of a Phase III trial showed pembrolizumab plus chemotherapy significantly improved survival in endometrial cancer.
List view / Grid view
National Cancer Institute (NCI)
news
First treatment approval for advanced ASPS
A Phase II trial has led to the FDA approval of atezolizumab for individuals over two years old with advanced alveolar soft part sarcoma.
news
Acting FDA Commissioner named
As Dr Scott Gottlieb steps down from his role next month, Dr Ned Sharpless has been announced as his short-term replacement...
news
Immunotherapy using tumour infiltrating lymphocytes for metastatic cancer
A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
news
Sorafenib improves progression-free survival for patients with rare sarcomas
A randomised clinical trial shows that the drug sorafenib tosylate extended progression-free survival compared with a placebo...
